• Ticker

DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

NovaMed, Inc.

NASDAQ:NOVA

$13.25 $0.00 (0.00%)

Quote as of

SciClone Reports Financial Results for the First Quarter 2012

SciClone Pharmaceuticals Is Dramatically Increasing Profits

SciClone Reports Financial Results for the Fourth Quarter and Year 2011 and Outlook for 2012

SciClone Pharmaceuticals reports initial revenue guidance for 2012

SciClone Provides 2011 Financial Update and Initial 2012 Guidance

SciClone Provides 2011 Financial Update and Initial 2012 Guidance

Health Robotics Continues Worldwide Expansion in Denmark With 2nd Generation Robots and Novamed

SciClone Reports Financial Results for the Third Quarter of 2011

SciClone Pharmaceuticals Announces Share Repurchase Program and Reaffirms 2011 Guidance

SciClone Reports Financial Results for the Second Quarter of 2011

SciClone: Novamed Acquisition Helps, But Questions Remain

SciClone Pharmaceuticals Provides First Quarter Results and Updates 2011 Guidance

SciClone Pharmaceuticals Provides First Quarter Results and Updates 2011 Guidance

Surgery Partners and NovaMed Complete Merger

NovaMed (NOVA) Reports Q1 Miss

SciClone boosts China sales power with $62M NovaMed acquisition

SciClone expands in China with $104.8 million NovaMed buy

SciClone (SCLN) Completes $105M Acquisition of NovaMed Pharma

SciClone buys U.S.-backed Chinese drug company

SciClone strikes $105M deal to buy China's NovaMed

SciClone sees combined FY11GAAP revenue $133M-$138M

SciClone acquires NovaMed

SciClone Acquires NovaMed Pharmaceuticals Further Establishing It as a Leading China-Focused Specialty Pharmaceutical Company

NovaMed to decide on buyout offer May

NovaMed announces anticipated effective date for merger with Surgery Partners

NovaMed reports Q4 cont ops EPS 26c vs. consensus 24c

NovaMed, Inc. investor files lawsuit against buyout

NovaMed sued over $13.25-a-share buyout

Faruqi & Faruqi, LLP Announces Shareholder Investigation Related to the Acquisition of NovaMed, Inc. - NOVA

Investigation Related to the Acquisition of NovaMed

Finkelstein Thompson LLP Announces Investigation of NovaMed Inc.

Finkelstein Thompson LLP Announces Investigation of NovaMed Inc.

Buyout of NovaMed Prompts Shareholder Claims Investigation by Goldfarb Branham Law Firm LLP

Buyout of NovaMed Prompts Shareholder Claims Investigation by Goldfarb Branham Law Firm LLP

Novamed To Go Private For $109 Million

Bull & Lifshitz, LLP Announces Investigation of the Acquisition of NovaMed, Inc.

Analyst Calls: CAB, DANG, FLT, FSLR, NOVA, NYX, OVTI, STJ, WD ...

Investor opposes NovaMed deal

NovaMed, Inc. directors face investor investigations over buyout

Ryan & Maniskas, LLP Announces Investigation of NovaMed, Inc.

See More Articles...